Vitamin D supplements in chronic kidney disease

References

• Handelman GJ, Levin NW. Guidelines for vitamin supplements in chronic kidney disease patients: What is the evidence? J Ren Nutr. 2011;21:117–119
   PubMed Web of Science ®Google Scholar
• Nigwekar SU, Tamez H, Thadhani RI. Vitamin D and chronic kidney disease–mineral bone disease (CKD–MBD). Bonekey Rep. 2014;3:498. doi: 10.1038/bonekey.2013.232
   PubMedGoogle Scholar
• Martin KJ, Gonzalez EA. Vitamin D supplementation in CKD. Clin Nephrol. 2011;75:286–293
   PubMed Web of Science ®Google Scholar
• Sterling KA, Eftekhari P, Girndt M, Kimmel PL, Raj DS. The immunoregulatory function of vitamin D: Implications in chronic kidney disease. Nat Rev Nephrol. 2012;8:403–412
   PubMed Web of Science ®Google Scholar
• Donate-Correa J, Dominguez-Pimentel V, Mendez-Perez ML, et al. Selective vitamin D receptor activation as anti-inflammatory target in chronic kidney disease. Mediat Inflamm. 2014;2014:670475
   PubMed Web of Science ®Google Scholar
• Alvarez JA, Ashraf A. Role of vitamin D in insulin secretion and insulin sensitivity for glucose homeostasis. Int J Endocrinol. 2010;2010:351385
   PubMed Web of Science ®Google Scholar
• Ding C, Gao D, Wilding J, Trayhurn P, Bing C. Vitamin D signalling in adipose tissue. Br J Nutr. 2012;108:1915–1923
   PubMed Web of Science ®Google Scholar
• Mithal A, Wahl DA, Bonjour JP, et al. Global vitamin D status and determinants of hypovitaminosis D. Osteoporos Int. 2009;20:1807–1820
   PubMed Web of Science ®Google Scholar
• Bouillon R, Okamura WH, Norman AW. Structure–function relationships in the vitamin D endocrine system. Endocr Rev. 1995;16:200–257
   PubMed Web of Science ®Google Scholar
• DeLuca HF. Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr. 2004;80:1689S–1696S
   PubMed Web of Science ®Google Scholar
• Jones G. Pharmacokinetics of vitamin D toxicity. Am J Clin Nutr. 2008;88:582S–586S
   PubMed Web of Science ®Google Scholar
• Santoro D, Caccamo D, Gagliostro G, et al. Vitamin D metabolism and activity as well as genetic variants of the vitamin D receptor (VDR) in chronic kidney disease patients. J Nephrol. 2013;26:636–644
   PubMed Web of Science ®Google Scholar
• Hollis BW. Assessment and interpretation of circulating 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D in the clinical environment. Endocrinol Metab Clin North Am. 2010;39:271–286, table of contents
   PubMed Web of Science ®Google Scholar
• Apukhovs'ka LI. physiologic functions of vitamin D3 and its metabolism in the body in normal states and in some pathologies. Ukr Biokhim Zh. 2000;72:138–146
   Google Scholar
• Hamano T. Vitamin D deficiency in CKD patients. Clin Calcium. 2007;17:718–724
   PubMedGoogle Scholar
• Echida Y, Mochizuki T, Uchida K, Tsuchiya K, Nitta K. Risk factors for vitamin D deficiency in patients with chronic kidney disease. Intern Med. 2012;51:845–850
   PubMed Web of Science ®Google Scholar
• Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. Kidney Int. 2007;71:31–38
   PubMed Web of Science ®Google Scholar
• Rouached M, El Kadiri Boutchich S, Al Rifai AM, Garabedian M, Fournier A. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. Kidney Int. 2008;74:389–390
   PubMed Web of Science ®Google Scholar
• Shimada T, Hasegawa H, Yamazaki Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004;19:429–435
   PubMed Web of Science ®Google Scholar
• Usatii M, Rousseau L, Demers C, et al. Parathyroid hormone fragments inhibit active hormone and hypocalcemia-induced 1,25(OH)2D synthesis. Kidney Int. 2007;72:1330–1335
   PubMed Web of Science ®Google Scholar
• de Boer IH, Thadhani R. Vitamin D deficiency: Consequence or cause of CKD? Clin J Am Soc Nephrol. 2013;8:1844–1846
   PubMed Web of Science ®Google Scholar
• Prentice A, Goldberg GR, Schoenmakers I. Vitamin D across the lifecycle: Physiology and biomarkers. Am J Clin Nutr. 2008;88:500S–506S
   PubMed Web of Science ®Google Scholar
• Dawson-Hughes B, Mithal A, Bonjour JP, et al. IOF position statement: Vitamin D recommendations for older adults. Osteoporos Int. 2010;21:1151–1154
   PubMed Web of Science ®Google Scholar
• American Geriatrics Society Workgroup on Vitamin D Supplementation for Older Adults. Recommendations abstracted from the American Geriatrics Society consensus statement on vitamin D for prevention of falls and their consequences. J Am Geriatr Soc. 2014;62:147–152
   PubMed Web of Science ®Google Scholar
• Bhan I, Hewison M, Thadhani R. Dietary vitamin D intake in advanced CKD/ESRD. Semin Dial. 2010;23:407–410
   PubMed Web of Science ®Google Scholar
• Skinner HG, Michaud DS, Giovannucci E, Willett WC, Colditz GA, Fuchs CS. Vitamin D intake and the risk for pancreatic cancer in two cohort studies. Cancer Epidemiol Biomarkers Prev. 2006;15:1688–1695
   PubMed Web of Science ®Google Scholar
• Scarmo S, Afanasyeva Y, Lenner P, et al. Circulating levels of 25-hydroxyvitamin D and risk of breast cancer: A nested case–control study. Breast Cancer Res. 2013;15:R15
   Google Scholar
• Cui Y, Rohan TE. Vitamin D, calcium, and breast cancer risk: A review. Cancer Epidemiol Biomarkers Prev. 2006;15:1427–1437
   PubMed Web of Science ®Google Scholar
• Spedding S, Vanlint S, Morris H, Scragg R. Does vitamin D sufficiency equate to a single serum 25-hydroxyvitamin D level or are different levels required for non-skeletal diseases? Nutrients. 2013;5:5127–5139
   PubMedGoogle Scholar
• Mehrotra R, Kermah D, Budoff M, et al. Hypovitaminosis d in chronic kidney disease. Clin J Am Soc Nephrol. 2008;3:1144–1151
   PubMed Web of Science ®Google Scholar
• Wolf M, Shah A, Gutierrez O, et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int. 2007;72:1004–1013
   PubMed Web of Science ®Google Scholar
• Mailliez S, Shahapuni I, Lecaque C, Massy ZA, Choukroun G, Fournier A. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int. 2008;74:389; author reply 389
   PubMed Web of Science ®Google Scholar
• Bhan I, Burnett-Bowie SA, Ye J, Tonelli M, Thadhani R. Clinical measures identify vitamin D deficiency in dialysis. Clin J Am Soc Nephrol. 2010;5:460–467
   PubMed Web of Science ®Google Scholar
• Orita H, Akizawa T. Outlines of K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Clin Calcium. 2004;14:693–697
   PubMedGoogle Scholar
• Galassi A, Bellasi A, Auricchio S, Papagni S, Cozzolino M. Which vitamin D in CKD–MBD? The time of burning questions. Biomed Res Int. 2013;2013:864012
   PubMed Web of Science ®Google Scholar
• Slatopolsky E, Finch J, Brown A. New vitamin D analogs. Kidney Int Suppl. 2003;63:S83–S87
   Google Scholar
• Kalantar-Zadeh K, Kovesdy CP. Clinical outcomes with active versus nutritional vitamin D compounds in chronic kidney disease. Clin J Am Soc Nephrol. 2009;4:1529–1539
   PubMed Web of Science ®Google Scholar
• Fujii H. CKD–MBD (chronic kidney disease–mineral and bone disorder). Effect of vitamin D on kidney and cardiovascular system. Clin Calcium. 2010;20:1045–1050
   PubMedGoogle Scholar
• Kennel KA, Drake MT, Hurley DL. Vitamin D deficiency in adults: When to test and how to treat. Mayo Clin Proc. 2010;85:752–757; quiz 757–758
   PubMed Web of Science ®Google Scholar
• Olgaard K, Lewin E, Silver J. Calcimimetics, vitamin D and advance in the management of CKD–MBD. Nephrol Dial Transplant. 2011;26:1117–1119
   PubMed Web of Science ®Google Scholar
• Kalantar-Zadeh K, Shah A, Duong U, Hechter RC, Dukkipati R, Kovesdy CP. Kidney bone disease and mortality in CKD: Revisiting the role of vitamin D, calcimimetics, alkaline phosphatase, and minerals. Kidney Int Suppl. 2010;117:S10–S21
   Google Scholar
• Williams S, Malatesta K, Norris K. Vitamin D and chronic kidney disease. Ethn Dis. 2009;19:S5–S8–S11
   Google Scholar
• Melamed ML, Astor B, Michos ED, Hostetter TH, Powe NR, Muntner P. 25-hydroxyvitamin D levels, race, and the progression of kidney disease. J Am Soc Nephrol. 2009;20:2631–2639
   PubMed Web of Science ®Google Scholar
• de Boer IH, Katz R, Chonchol M, et al. Serum 25-hydroxyvitamin D and change in estimated glomerular filtration rate. Clin J Am Soc Nephrol. 2011;6:2141–2149
   PubMed Web of Science ®Google Scholar
• Inda Filho AJ, Melamed ML. Vitamin D and kidney disease: What we know and what we do not know. J Bras Nefrol. 2013;35:323–331
   PubMedGoogle Scholar
• de Boer IH, Ioannou GN, Kestenbaum B, Brunzell JD, Weiss NS. 25-Hydroxyvitamin D levels and albuminuria in the third national health and nutrition examination survey (NHANES III). Am J Kidney Dis. 2007;50:69–77
   PubMed Web of Science ®Google Scholar
• Agarwal R. Vitamin D, proteinuria, diabetic nephropathy, and progression of CKD. Clin J Am Soc Nephrol. 2009;4:1523–1528
   PubMed Web of Science ®Google Scholar
• Fishbane S, Chittineni H, Packman M, Dutka P, Ali N, Durie N. Oral paricalcitol in the treatment of patients with CKD and proteinuria: A randomized trial. Am J Kidney Dis. 2009;54:647–652
   PubMed Web of Science ®Google Scholar
• Alborzi P, Patel NA, Peterson C, et al. Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: A randomized double-blind pilot trial. Hypertension. 2008;52:249–255
   PubMed Web of Science ®Google Scholar
• de Zeeuw D, Agarwal R, Amdahl M, et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (vital study): A randomised controlled trial. Lancet. 2010;376:1543–1551
   PubMed Web of Science ®Google Scholar
• Liu LJ, Lv JC, Shi SF, Chen YQ, Zhang H, Wang HY. Oral calcitriol for reduction of proteinuria in patients with IgA nephropathy: A randomized controlled trial. Am J Kidney Dis. 2012;59:67–74
   PubMed Web of Science ®Google Scholar
• Agarwal R, Hynson JE, Hecht TJ, Light RP, Sinha AD. Short-term vitamin D receptor activation increases serum creatinine due to increased production with no effect on the glomerular filtration rate. Kidney Int. 2011;80:1073–1079
   PubMed Web of Science ®Google Scholar
• de Borst MH, Hajhosseiny R, Tamez H, Wenger J, Thadhani R, Goldsmith DJ. Active vitamin D treatment for reduction of residual proteinuria: A systematic review. J Am Soc Nephrol. 2013;24:1863–1871
   PubMed Web of Science ®Google Scholar
• Forman JP, Giovannucci E, Holmes MD, et al. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. Hypertension. 2007;49:1063–1069
   PubMed Web of Science ®Google Scholar
• Forman JP, Curhan GC, Taylor EN. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension among young women. Hypertension. 2008;52:828–832
   PubMed Web of Science ®Google Scholar
• Pfeifer M, Begerow B, Minne HW, Abrams C, Nachtigall D, Hansen C. Effects of a short-term vitamin D and calcium supplementation on body sway and secondary hyperparathyroidism in elderly women. J Bone Miner Res. 2000;15:1113–1118
   PubMed Web of Science ®Google Scholar
• Pfeifer M, Begerow B, Minne HW, Nachtigall D, Hansen C. Effects of a short-term vitamin D(3) and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J Clin Endocrinol Metab. 2001;86:1633–1637
   PubMed Web of Science ®Google Scholar
• Pittas AG, Chung M, Trikalinos T, et al. Systematic review: Vitamin D and cardiometabolic outcomes. Ann Intern Med. 2010;152:307–314
   PubMed Web of Science ®Google Scholar
• Palmer SC, McGregor DO, Craig JC, Elder G, Macaskill P, Strippoli GF. Vitamin D compounds for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev. 2009;4:CD008175
   PubMed Web of Science ®Google Scholar
• Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin–angiotensin system. J Clin Invest. 2002;110:229–238
   PubMed Web of Science ®Google Scholar
• Xiang W, Kong J, Chen S, et al. Cardiac hypertrophy in vitamin D receptor knockout mice: Role of the systemic and cardiac renin–angiotensin systems. Am J Physiol Endocrinol Metab. 2005;288:E125–E132
   PubMed Web of Science ®Google Scholar
• Mizobuchi M, Morrissey J, Finch JL, et al. Combination therapy with an angiotensin-converting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats. J Am Soc Nephrol. 2007;18:1796–1806
   PubMed Web of Science ®Google Scholar
• Tan X, Li Y, Liu Y. Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy. J Am Soc Nephrol. 2006;17:3382–3393
   PubMed Web of Science ®Google Scholar
• Tan X, Wen X, Liu Y. Paricalcitol inhibits renal inflammation by promoting vitamin D receptor-mediated sequestration of nf-kappab signaling. J Am Soc Nephrol. 2008;19:1741–1752
   PubMed Web of Science ®Google Scholar
• Kong J, Kim GH, Wei M, et al. Therapeutic effects of vitamin D analogs on cardiac hypertrophy in spontaneously hypertensive rats. Am J Pathol. 2010;177:622–631
   PubMed Web of Science ®Google Scholar
• Martins D, Wolf M, Pan D, et al. Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the united states: Data from the third national health and nutrition examination survey. Arch Intern Med. 2007;167:1159–1165
   PubMed Web of Science ®Google Scholar
• de Boer IH, Kestenbaum B, Shoben AB, Michos ED, Sarnak MJ, Siscovick DS. 25-Hydroxyvitamin D levels inversely associate with risk for developing coronary artery calcification. J Am Soc Nephrol. 2009;20:1805–1812
   PubMed Web of Science ®Google Scholar
• Wang TJ, Pencina MJ, Booth SL, et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation. 2008;117:503–511
   PubMed Web of Science ®Google Scholar
• Mehrotra R, Kermah DA, Salusky IB, et al. Chronic kidney disease, hypovitaminosis D, and mortality in the united states. Kidney Int. 2009;76:977–983
   PubMed Web of Science ®Google Scholar
• Park CW, Oh YS, Shin YS, et al. Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis. 1999;33:73–81
   PubMed Web of Science ®Google Scholar
• Wang L, Manson JE, Song Y, Sesso HD. Systematic review: Vitamin D and calcium supplementation in prevention of cardiovascular events. Ann Intern Med. 2010;152:315–323
   PubMed Web of Science ®Google Scholar
• Thadhani R, Appelbaum E, Pritchett Y, et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: The primo randomized controlled trial. JAMA. 2012;307:674–684
   PubMed Web of Science ®Google Scholar
• Canziani ME, Tomiyama C, Higa A, Draibe SA, Carvalho AB. Fibroblast growth factor 23 in chronic kidney disease: Bridging the gap between bone mineral metabolism and left ventricular hypertrophy. Blood Purif. 2011;31:26–32
   PubMed Web of Science ®Google Scholar
• Merino A, Nogueras S, Buendia P, et al. Microinflammation and endothelial damage in hemodialysis. Contrib Nephrol. 2008;161:83–88
   PubMed Web of Science ®Google Scholar
• Lang CL, Wang MH, Chiang CK, Lu KC. Vitamin D and the immune system from the nephrologist's viewpoint. ISRN Endocrinol. 2014;2014:105456
   Google Scholar
• Lang CL, Wang MH, Hung KY, Chiang CK, Lu KC. Altered molecular repertoire of immune system by renal dysfunction in the elderly: Is prediction and targeted prevention in the horizon? EPMA J. 2013;4(1):17. doi: 10.1186/1878-5085-4-17
   PubMedGoogle Scholar
• Stubbs JR, Idiculla A, Slusser J, Menard R, Quarles LD. Cholecalciferol supplementation alters calcitriol-responsive monocyte proteins and decreases inflammatory cytokines in ESRD. J Am Soc Nephrol. 2010;21:353–361
   PubMed Web of Science ®Google Scholar
• Bucharles S, Barberato SH, Stinghen AE, et al. Impact of cholecalciferol treatment on biomarkers of inflammation and myocardial structure in hemodialysis patients without hyperparathyroidism. J Ren Nutr. 2012;22:284–291
   PubMed Web of Science ®Google Scholar
• Pilz S, Iodice S, Zittermann A, Grant WB, Gandini S. Vitamin D status and mortality risk in CKD: A meta-analysis of prospective studies. Am J Kidney Dis. 2011;58:374–382
   PubMed Web of Science ®Google Scholar
• Arabi A, El Rassi R, El-HajjFuleihan G. Hypovitaminosis D in developing countries-prevalence, risk factors and outcomes. Nat Rev Endocrinol. 2010;6:550–561
   PubMed Web of Science ®Google Scholar
• Winkelmann BR, Marz W, Boehm BO, et al. Rationale and design of the LURIC study – a resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovascular disease. Pharmacogenomics. 2001;2:S1–S73
   PubMed Web of Science ®Google Scholar
• Holick MF. Optimal vitamin D status for the prevention and treatment of osteoporosis. Drugs Aging. 2007;24:1017–1029
   PubMed Web of Science ®Google Scholar
• Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson-Hughes B. Fracture prevention with vitamin D supplementation: A meta-analysis of randomized controlled trials. JAMA. 2005;293:2257–2264
   PubMed Web of Science ®Google Scholar
• Dawson-Hughes B, Heaney RP, Holick MF, Lips P, Meunier PJ, Vieth R. Estimates of optimal vitamin D status. Osteoporos Int. 2005;16:713–716
   PubMed Web of Science ®Google Scholar
• Arenas MD, Alvarez-Ude F, Torregrosa V, et al. Consequences of the implementation of K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease in a population of patients on chronic hemodialysis. J Nephrol. 2007;20:453–461
   PubMed Web of Science ®Google Scholar
• Dusso AS, Finch J, Brown A, et al. Extrarenal production of calcitriol in normal and uremic humans. J Clin Endocrinol Metab. 1991;72:157–164
   PubMed Web of Science ®Google Scholar
• Alvarez J, Wasse H, Tangpricha V. Vitamin D supplementation in pre-dialysis chronic kidney disease: A systematic review. Dermatoendocrinology. 2012;4:118–127
   PubMedGoogle Scholar
• Kandula P, Dobre M, Schold JD, Schreiber MJ Jr, Mehrotra R, Navaneethan SD. Vitamin D supplementation in chronic kidney disease: A systematic review and meta-analysis of observational studies and randomized controlled trials. Clin J Am Soc Nephrol. 2011;6:50–62
   PubMed Web of Science ®Google Scholar
• Bhan I, Camargo CA, Jr Wenger J, et al. Circulating levels of 25-hydroxyvitamin D and human cathelicidin in healthy adults. J Allergy Clin Immunol. 2011;127:1302–1304, e1301
   PubMed Web of Science ®Google Scholar
• Palmer SC, McGregor DO, Craig JC, Elder G, Macaskill P, Strippoli GF. Vitamin D compounds for people with chronic kidney disease requiring dialysis. Cochrane Database Syst Rev. 2009;4:CD005633
   PubMed Web of Science ®Google Scholar
• Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int. 2003;63:1483–1490
   PubMed Web of Science ®Google Scholar
• Hansen D, Rasmussen K, Pedersen SM, Rasmussen LM, Brandi L. Changes in fibroblast growth factor 23 during treatment of secondary hyperparathyroidism with alfacalcidol or paricalcitol. Nephrol Dial Transplant. 2012;27:2263–2269
   PubMed Web of Science ®Google Scholar
• Moe S, Wazny LD, Martin JE. Oral calcitriol versus oral alfacalcidol for the treatment of secondary hyperparathyroidism in patients receiving hemodialysis: A randomized, crossover trial. Can J Clin Pharmacol. 2008;15:e36–e43
   Google Scholar